Primary Immunodeficiency Diseases clinical trials at UC Davis
1 research study open to eligible people
Showing trials for
Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases
open to all eligible people
The purpose of this study is to assess the efficacy and safety of tabelecleucel in participants with Epstein-Barr virus (EBV) associated diseases.
Sacramento, California and other locations
Our lead scientists for Primary Immunodeficiency Diseases research studies include Mehrdad Abedi, MD.
Last updated: